Advanced Drug Delivery Reviews, Год журнала: 2020, Номер 170, С. 1 - 25
Опубликована: Дек. 24, 2020
Язык: Английский
Journal of Infection, Год журнала: 2020, Номер 80(6), С. e14 - e18
Опубликована: Март 27, 2020
Due to the general susceptibility of new coronaviruses, clinical characteristics and outcomes elderly young patients may be different.To analyze with 2019 new-type coronavirus pneumonia (COVID-19).This is a retrospective study (COVID-19) who were hospitalized in Hainan Provincial People's Hospital from January 15, 2020 February 18, 2020. Compare Young Middle-aged patients.A total 56 enrolled 18 (32.14%), 38 middle-aged (67.86%). The most common symptoms both groups fever, followed by cough sputum. Four group received negative pressure ICU for mechanical ventilation, five group. One patient died (5.56%), two (5.26%). PSI score was higher than that (P < 0.001). proportion grades IV V significantly 0.05). multiple lobe involvement 0.001), there no difference single lesions between groups. lymphocytes lower C-reactive protein Lopinavir Ritonavir Tablets, Chinese medicine, oxygen therapy, ventilation statistically different group, P values all <0.05.The mortality COVID-19 patients, grade patients. Elderly are more likely progress severe disease.
Язык: Английский
Процитировано
1676
Science, Год журнала: 2020, Номер 369(6499), С. 77 - 81
Опубликована: Май 6, 2020
Vaccine candidate tested in monkeys Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent race develop a vaccine. Gao et al. report preclinical results early vaccine called PiCoVacc, which protected rhesus macaque against SARS-CoV-2 infection when analyzed short-term studies. The researchers obtained multiple strains from 11 hospitalized patients across the world and then chemically inactivated harmful properties virus. Animals were immunized with one two doses inoculated SARS-CoV-2. Those that received lowest dose showed signs controlling infection, those receiving highest appeared more did not have detectable viral loads pharynx or lungs at 7 days after infection. next steps will be testing for safety efficacy humans. Science , this issue p. 77
Язык: Английский
Процитировано
1469
Journal of Internal Medicine, Год журнала: 2020, Номер 288(2), С. 192 - 206
Опубликована: Апрель 29, 2020
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2, a novel from the same family as SARS-CoV and Middle East coronavirus, has spread worldwide leading World Health Organization to declare pandemic. The disease caused by SARS-CoV-2, 2019 (COVID-19), presents flu-like symptoms which can become serious in high-risk individuals. Here, we provide an overview of known clinical features treatment options for COVID-19. We carried out systematic literature search using main online databases (PubMed, Google Scholar, MEDLINE, UpToDate, Embase Web Science) with following keywords: 'COVID-19', '2019-nCoV', 'coronavirus' 'SARS-CoV-2'. included publications 1 January 3 April 2020 focused on treatments. found that infection is transmitted human through contact contaminated environmental surfaces. Hand hygiene fundamental prevent contamination. Wearing personal protective equipment recommended specific environments. COVID-19 are fever, cough, fatigue, slight dyspnoea, sore throat, headache, conjunctivitis gastrointestinal issues. Real-time PCR used diagnostic tool nasal swab, tracheal aspirate or bronchoalveolar lavage samples. Computed tomography findings important both diagnosis follow-up. To date, there no evidence any effective therapies being treat antiviral drugs, chloroquine/hydroxychloroquine therapy. In conclusion, although many have been proposed, quarantine only intervention appears be decreasing contagion rate. Specifically designed randomized trials needed determine most appropriate evidence-based modality.
Язык: Английский
Процитировано
1358
Allergy, Год журнала: 2020, Номер 75(7), С. 1564 - 1581
Опубликована: Май 12, 2020
As a zoonotic disease that has already spread globally to several million human beings and possibly domestic wild animals, eradication of coronavirus 2019 (COVID-19) appears practically impossible. There is pressing need improve our understanding the immunology this contain pandemic by developing vaccines medicines for prevention treatment patients. In review, we aim on immune response immunopathological changes in patients linked deteriorating clinical conditions such as cytokine storm, acute respiratory distress syndrome, autopsy findings acute-phase reactants, serum biochemistry COVID-19. Similar many other viral infections, asymptomatic present significant but currently unknown fraction affected individuals. majority patients, 1-week, self-limiting typically occurs, which ends with development neutralizing antiviral T cell antibody immunity. The IgM-, IgA-, IgG-type virus-specific antibodies levels are important measurements predict population immunity against whether cross-reactivity coronaviruses taking place. High load during first infection repeated exposure virus especially healthcare workers can be an factor severity disease. It should noted aspects severe unique COVID-19 rarely observed lymphopenia eosinopenia, extensive pneumonia lung tissue damage, storm leading multiorgan failure. Lymphopenia causes defect regulatory At same time, starts activation cytokine-secreting cells innate adaptive mechanisms both contribute poor prognosis. Elevated reactants early predictors high severity. Prevention disease, novel approaches prevent their will main routes future research areas. learn live amidst virus, assist containing treat individual
Язык: Английский
Процитировано
1123
Diabetes & Metabolic Syndrome Clinical Research & Reviews, Год журнала: 2020, Номер 14(4), С. 407 - 412
Опубликована: Апрель 18, 2020
Язык: Английский
Процитировано
1074
Nature reviews. Immunology, Год журнала: 2020, Номер 20(10), С. 615 - 632
Опубликована: Сен. 4, 2020
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It widely believed that prepandemic normalcy will never return until safe and effective vaccine strategy becomes available global vaccination programme implemented successfully. Here, we discuss immunological principles need be taken into consideration development of COVID-19 strategies. On basis these principles, examine current candidates, their strengths potential shortfalls, make inferences about chances success. Finally, scientific practical challenges faced process developing successful ways which strategies may evolve over next few years. This Review outlines guiding for design analyses landscape ahead.
Язык: Английский
Процитировано
1035
Signal Transduction and Targeted Therapy, Год журнала: 2020, Номер 5(1)
Опубликована: Июль 25, 2020
Abstract The recent novel coronavirus disease (COVID-19) outbreak, caused by severe acute respiratory syndrome 2 (SARS-CoV-2), is seeing a rapid increase in infected patients worldwide. host immune response to SARS-CoV-2 appears play critical role pathogenesis and clinical manifestations. not only activates antiviral responses, but can also cause uncontrolled inflammatory responses characterized marked pro-inflammatory cytokine release with COVID-19, leading lymphopenia, lymphocyte dysfunction, granulocyte monocyte abnormalities. These SARS-CoV-2-induced abnormalities may lead infections microorganisms, septic shock, multiple organ dysfunction. Therefore, mechanisms underlying COVID-19 must be elucidated guide management of the disease. Moreover, rational SARS-CoV-2, which includes enhancing anti-viral immunity while inhibiting systemic inflammation, key successful treatment. In this review, we discuss immunopathology its potential mechanisms, implications aid development new therapeutic strategies against COVID-19.
Язык: Английский
Процитировано
852
The Lancet Infectious Diseases, Год журнала: 2020, Номер 20(11), С. e276 - e288
Опубликована: Авг. 17, 2020
As severe acute respiratory syndrome coronavirus 2 continues to spread worldwide, there have been increasing reports from Europe, North America, Asia, and Latin America describing children adolescents with COVID-19-associated multisystem inflammatory conditions. However, the association between in COVID-19 is still unknown. We review epidemiology, causes, clinical features, current treatment protocols for associated COVID-19. also discuss possible underlying pathophysiological mechanisms COVID-19-induced processes, which can lead organ damage paediatric patients who are severely ill. These insights provide evidence need develop a clear case definition protocol this new condition shed light on future therapeutic interventions potential vaccine development. TRANSLATIONS: For French, Chinese, Arabic, Spanish Russian translations of abstract see Supplementary Materials section.
Язык: Английский
Процитировано
795
Journal of Clinical Virology, Год журнала: 2020, Номер 127, С. 104371 - 104371
Опубликована: Апрель 14, 2020
Язык: Английский
Процитировано
694
Clinical Immunology, Год журнала: 2020, Номер 215, С. 108448 - 108448
Опубликована: Апрель 27, 2020
Язык: Английский
Процитировано
658